

## EQA round: T12/24 - Glycated Haemoglobin (study)

Deadline: 1.11.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D<sub>max</sub> = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U<sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessedN<sub>out</sub> = number of the results removed before calculationN<sub>suc</sub> = number of successful resultsS<sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability								
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
(220) Haemoglobin A <sub>1c</sub>	[mmol/mol]				176							176	170	97	
<b>Sample A</b>		59,7	1,9	3,2	176		CVP	59,7	0,36	asym.	53	66	176	170	97
(14) Bio-Rad		59,2	1,5	2,6	43	0							43		
(25) TOSOH		61,2	1,4	2,3	46	0							46		
(34) Sebia		59	1,5	2,5	8	0							8		
(60) Roche		59,5	1,3	2,2	14	0							14		
(150) Arkray		59,5	1,9	3,2	53	0							53		
Other					12	0							12		
							3x 1, 2x 46, 3x 58, 1x 162, 2x 177, 1x 999								